Unlike on a visit to Capitol Hill last year, Janet Yellen didn’t criticize biotech valuations when she went before Congress this week. But that doesn’t mean investors should let their guard down.

Since the Federal Reserve chairwoman last July used biotech stocks as an example of possible froth, the sector has mostly shot higher. In fact, over the past two years, the Nasdaq Biotechnology Index has outperformed the NYSE Arca...